Column Group III Gp, LP has bought stock on 12 days since Jan 2023
10% owner at Tenaya Therapeutics, Inc., and 1 other company
SEC CIK 0001790965 · Filings on SEC.gov ↗
Column Group III Gp, LP's record
3 months after each buy, from the first price a copier could get.
12 buys since 2023 with 3 months of prices.
Companies
Every filing
15 filings since Jan 2023, newest first
Tenaya Therapeutics, Inc.
10% owner
Tenaya Therapeutics, Inc.
10% owner
Tenaya Therapeutics, Inc.
10% owner
Surrozen, Inc./De
10% owner
Surrozen, Inc./De
10% owner
Surrozen, Inc./De
10% owner
Surrozen, Inc./De
10% owner
Surrozen, Inc./De
10% owner
Surrozen, Inc./De
10% owner
Tenaya Therapeutics, Inc.
10% owner
Surrozen, Inc./De
10% owner
Tenaya Therapeutics, Inc.
10% owner
Tenaya Therapeutics, Inc.
10% owner
Tenaya Therapeutics, Inc.
10% owner
Tenaya Therapeutics, Inc.
10% owner
About Column Group III Gp, LP
Column Group III GP, LP is the general partner of The Column Group III LP, a venture capital fund managed by The Column Group (TCG), a San Francisco-based firm dedicated to fueling life sciences innovation through company formation and investments across the development lifecycle.( Established with a $239.5 million fundraise in 2016, it operates as a Venture Capital Fund focused on biotech, with offices at 1700 Owens Street, San Francisco, CA, and is audited by KPMG.(
As a corporate insider, Column Group III GP, LP holds significant stakes in portfolio companies, including approximately 34% ownership in Surrozen, Inc. (SRZN) as of recent 13D/G filings (1,265,276 shares valued at around $18 million), with transactions reported in 2025, and is also a 10% owner of Revolution Medicines Inc. (RVMD) with over 5.9 million shares.( TCG, its affiliate manager, is led by Founder and Managing Partner Peter Svennilson (35+ years in VC, founded companies sold to J&J and Roche), Managing Partner Tim Kutzkey, Ph.D. (involved in Surrozen's founding), and other partners like Haijun Chen, Ph.D., with a team of scientific and operational experts supporting investments in areas like targeted protein stabilization and therapeutics.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.